Found: 6
Select item for more details and to access through your institution.
İki Ayda Bir Enjektabl Uzun Etkili Cabotegravir + Rilpivirin (CAB + RPV) Tedavi Rejimi: ATLAS-2M Çalışması 152. Hafta Sonuçları.
- Published in:
- Mediterranean Journal of Infection, Microbes & Antimicrobials, 2022, v. 11, p. 129
- By:
- Publication type:
- Article
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 9, p. 1646, doi. 10.1093/cid/ciad020
- By:
- Publication type:
- Article
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study
- Published in:
- Clinical Infectious Diseases, 2016, v. 63, n. 1, p. 122, doi. 10.1093/cid/ciw207
- By:
- Publication type:
- Article
Long-Acting Cabotegravir+Rilpivirine Every 2 Months: ATLAS-2M Week 152 Results.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. 276
- By:
- Publication type:
- Article
Long-acting cabotegravir+rilpivirine every 2 months: ATLAS-2M week 152 results.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. S310
- By:
- Publication type:
- Article
DTG+3TC vs DTG+TDF/FTC (GEMINI-1&-2): Confirmed Virologic Withdrawals Through Week 96.
- Published in:
- Infection & Chemotherapy, 2020, v. 52, p. S376
- By:
- Publication type:
- Article